DIESSE announces a strategic partnership with Grifols to distribute tests for biological drug monitoring in Italy

Siena, 1st August 2022 – DIESSE Diagnostica Senese has announced a strategic agreement with Grifols for the distribution of Grifols' Promonitor assays portfolio, either on ELISA microplates or as a point of care technology (POCT), in Italy. Monitoring biological drugs and anti-drug-antibodies provides precious diagnostic information to customize the treatment in patients with chronic inflammatory diseases.

DIESSE and Grifols have been business partners for many years and both companies have a strategic collaboration to develop new technologies in the clinical-diagnostics area of biological drug monitoring. This partnership is expressed at a global level with the availability of Promonitor tests on CHORUS system as a mono-test, enriching the over 150 tests available in the analytic menu of the instrument.

This further collaboration in the Italian area rounds out the solutions for biological drug assays. Customers can now use Promonitor kit on ELISA microplate and Promonitor Quick kit with dedicated reader, an easy-to-use and rapid POCT that can be used also in the doctor's office because no laboratory equipment is needed.

“The fruitful collaboration with Grifols continues: it represents a strategic value and a constant commitment to offer quality and innovative technology,” states Luigi Nava, Commercial Operations Director of DIESSE. “We can offer Italian customers the entire portfolio of available solutions: this is a renewed responsibility and a promise for a qualitative and professional service, to concretely support our will of partnership."

"Grifols is committed to providing advanced technology solutions such as our Promonitor diagnostic testing portfolio to ensure safe and high-quality biological drug monitoring for patients,” says Guillermo Marco-Gardoqui, vice president, Diagnostic Operations, Grifols.

This agreement confirms our commitment in providing the highest quality for each test and for each diagnostic information, in order to detect and evaluate Immune System alterations.